Q2 2025 Management View David J. Moss announced his appointment as Chief Executive Officer following the retirement of ...

Company to Host Conference Call Today, August 7th, at 4:30pm ETBOCA RATON, Fla., Aug. 07, 2025 (GLOBE NEWSWIRE) -- INmune Bio Inc. (NASDAQ: INMB) (the “Company”), a clinical-stage immunology company ...

XPro failed to meet primary endpoints in its Phase 2 Alzheimer’s trial, but showed some positive signals in a biomarker-enriched subgroup. Cash and cash equivalents increased to $33.4 million, ...

INmune Bio Inc. (NASDAQ:INMB) saw its stock jump 28% on Monday after announcing that its Phase I/II trial evaluating INKmune™ ...

Thank you, operator, and good afternoon, everyone. We thank you for joining us for the call for INmune Bio's second quarter 2025 financial results. Presenting on today's call are David Moss, ...

Following the announcement of TNF inhibitor, INmune Bio Inc. stock surged by 24.72% in after-hours trading on Friday.

INmune Bio Inc. (NASDAQ: INMB) (the "Company"), a clinical-stage immunology and inflammation company, is pleased to report that its Phase I/II trial (the “CaRe PC” trial) of INKmune™ for men with ...

Shares of INmune Bio climbed after the biotech company said its trial for treatment of a certain prostate cancer met its targets. The stock was up 11%, to $2.83, but is still down 65% over the ...

INmune Bio Inc. (NASDAQ: INMB) announced today that a video detailing the additional findings from the Phase 2 MINDFuL trial evaluating XPro™, ...

INmune Bio Contact: David Moss, CFO (858) 964-3720 info@inmunebio.com Investor Contact: Jason Nelson Core IR (516) 842-9614 x-823 ...

Both Cassava Sciences and INmune Bio have brought impressive results on neuroinflammation and neurodegeneration. I expect INmune Bio’s XPro to yield impressive results in its phase 2 trials like ...

INmune Bio, Inc. is a publicly traded (NASDAQ: INMB), clinical-stage biotechnology company focused on developing treatments that target the innate immune system to fight disease.